Pharma Equity Group A/S Stock

Pharma Equity Group A/S ROE

The Return on Equity (ROE) of Pharma Equity Group A/S (PEG.CO) as of Aug 15, 2026 is -99.65 %. In the previous year, Return on Equity (ROE) was -49.97 % — a change of 99.42% (lower).

ROE

-99.65 %

YoY

99.42%

Last updated:

In 2026, Pharma Equity Group A/S's return on equity (ROE) was -99.65 %, a 99.42% increase from the -49.97 % ROE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Pharma Equity Group A/S Stock analysis

What does Pharma Equity Group A/S do? Blue Vision A/S is a company specializing in the development, production, and marketing of underwater technology. It was founded in 1992 and is headquartered in Holstebro, Denmark. The company focuses on underwater lighting, underwater inspection cameras, and underwater communication. It specializes in manufacturing underwater lighting products for the offshore industry, ports, and shipping. It also produces underwater inspection cameras for inspecting underwater structures without the need for divers. In addition, the company has developed devices for underwater communication, which are crucial in the offshore industry and military sector. Blue Vision A/S emphasizes innovation and technology, holding patents and investing in digital technology to improve inspection systems. In summary, Blue Vision A/S specializes in underwater technology and offers solutions for the offshore industry, ports, and shipping. The company is committed to innovation and technology to provide the best solutions to its customers. Pharma Equity Group A/S is one of the most popular companies on Eulerpool.

ROE Details

Decoding Pharma Equity Group A/S's Return on Equity (ROE)

Pharma Equity Group A/S's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Pharma Equity Group A/S's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Pharma Equity Group A/S's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Pharma Equity Group A/S’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Pharma Equity Group A/S stock

Return on Equity (ROE) of Pharma Equity Group A/S is -99.65 % in 2026.

Return on Equity (ROE) of Pharma Equity Group A/S changed from -49.97 % to -99.65 %, representing a 99.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Pharma Equity Group A/S since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Pharma Equity Group A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Pharma Equity Group A/S

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Pharma Equity Group A/S